Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 7.57% is 70% below its 5-year average of 25.12%, near the low end of its 5-year range (0.97%–38.34%).
As of the fiscal period ended Tuesday, June 30, 2026. 71.32% below its 12-month average of 26.39%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 7.57%.
RETURN ON EQUITY (ROE)
7.57%
RETURN ON EQUITY (ROE) AVG TTM
26.39%
RETURN ON EQUITY (ROE) AVG 3Y
22.28%
RETURN ON EQUITY (ROE) AVG 5Y
25.12%
RETURN ON EQUITY (ROE) AVG 10Y
23.16%
RETURN ON EQUITY (ROE) AVG 15Y
19.82%
RETURN ON EQUITY (ROE) AVG 20Y
20.63%
CURRENT VS TTM AVG
-71.32%
CURRENT VS 3Y AVG
-66.04%
CURRENT VS 5Y AVG
-69.87%
CURRENT VS 10Y AVG
-67.32%
CURRENT VS 15Y AVG
-61.81%
CURRENT VS 20Y AVG
-63.33%
SECTOR MEDIAN · HEALTHCARE
13.01%
median of 84 covered companies
CURRENT VS SECTOR MEDIAN
-41.84%
vs the sector median at left
Merck & Co., Inc.
Market Cap
$355.81B
Return on Equity (ROE)
7.57%
TTM Avg
26.39%
3Y Avg
22.28%
5Y Avg
25.12%
Market Cap
$353.63B
Return on Equity (ROE)
38.06%
TTM Avg
32.06%
3Y Avg
36.93%
5Y Avg
40.66%
Market Cap
$343.42B
Return on Equity (ROE)
14.34%
TTM Avg
14.18%
3Y Avg
19.86%
5Y Avg
21.18%
Market Cap
$253.52B
Return on Equity (ROE)
20.79%
TTM Avg
19.16%
3Y Avg
15.60%
5Y Avg
13.86%
Market Cap
$464.91B
Return on Equity (ROE)
N/A
TTM Avg
-0.29%
3Y Avg
28.74%
5Y Avg
37.53%
Market Cap
$240.66B
Return on Equity (ROE)
13.25%
TTM Avg
12.70%
3Y Avg
13.51%
5Y Avg
15.24%
Market Cap
$203.83B
Return on Equity (ROE)
74.80%
TTM Avg
79.33%
3Y Avg
111.35%
5Y Avg
101.76%
Market Cap
$186.25B
Return on Equity (ROE)
53.50%
TTM Avg
61.58%
3Y Avg
67.05%
5Y Avg
123.42%
Market Cap
$184.26B
Return on Equity (ROE)
-27.39%
TTM Avg
19.98%
3Y Avg
21.60%
5Y Avg
19.44%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Merck & Co., Inc. (MRK) | $355.81B | 7.57% | 26.39% | 22.28% | 25.12% |
| Roche Holding AG (RHHBY)vs › | $353.63B | 38.06% | 32.06% | 36.93% | 40.66% |
| UnitedHealth Group Incorporated (UNH)vs › | $343.42B | 14.34% | 14.18% | 19.86% | 21.18% |
| AstraZeneca PLC (AZN)vs › | $253.52B | 20.79% | 19.16% | 15.60% | 13.86% |
| AbbVie Inc. (ABBV)vs › | $464.91B | N/A | -0.29% | 28.74% | 37.53% |
| Thermo Fisher Scientific Inc. (TMO)vs › | $240.66B | 13.25% | 12.70% | 13.51% | 15.24% |
| Amgen Inc. (AMGN)vs › | $203.83B | 74.80% | 79.33% | 111.35% | 101.76% |
| Novo Nordisk A/S (NVO)vs › | $186.25B | 53.50% | 61.58% | 67.05% | 123.42% |
| Gilead Sciences, Inc. (GILD)vs › | $184.26B | -27.39% | 19.98% | 21.60% | 19.44% |
| Abbott Laboratories (ABT)vs › | $178.30B | 10.61% | 20.32% | 18.59% | 17.97% |
ROE
7.6%
ROA
2.4%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 7.57% |
| 2026-03-31 | 19.48% |
| 2025-12-31 | 34.70% |
| 2025-09-30 | 36.71% |
| 2025-06-30 | 33.49% |
| 2025-03-31 | 36.07% |
| 2024-12-31 | 36.96% |
| 2024-09-30 | 27.30% |
| 2024-06-30 | 31.52% |
| 2024-03-31 | 5.71% |
| 2023-12-31 | 0.97% |
| 2023-09-30 | 11.17% |
| 2023-06-30 | 8.04% |
| 2023-03-31 | 27.82% |
| 2022-12-31 | 31.57% |
| 2022-09-30 | 34.32% |
| 2022-06-30 | 38.34% |
| 2022-03-31 | 34.68% |
| 2021-12-31 | 34.17% |
| 2021-09-30 | 20.11% |
| 2021-06-30 | 16.73% |
| 2021-03-31 | 26.08% |
| 2020-12-31 | 27.92% |
| 2020-09-30 | 39.46% |
| 2020-06-30 | 37.91% |
| 2020-03-31 | 38.72% |
| 2019-12-31 | 37.99% |
| 2019-09-30 | 34.70% |
| 2019-06-30 | 33.88% |
| 2019-03-31 | 30.50% |
| 2018-12-31 | 23.30% |
| 2018-09-30 | 10.32% |
| 2018-06-30 | 4.12% |
| 2018-03-31 | 4.69% |
| 2017-12-31 | 6.98% |
| 2017-09-30 | 7.44% |
| 2017-06-30 | 12.89% |
| 2017-03-31 | 10.91% |
| 2016-12-31 | 9.78% |
| 2016-09-30 | 12.55% |
| 2016-06-30 | 11.84% |
| 2016-03-31 | 10.54% |
| 2015-12-31 | 9.94% |
| 2015-09-30 | 23.65% |
| 2015-06-30 | 21.21% |
| 2015-03-31 | 23.38% |
| 2014-12-31 | 24.50% |
| 2014-09-30 | 11.91% |
| 2014-06-30 | 11.61% |
| 2014-03-31 | 9.04% |
| 2013-12-31 | 8.85% |
| 2013-09-30 | 9.55% |
| 2013-06-30 | 10.81% |
| 2013-03-31 | 11.36% |
| 2012-12-31 | 11.63% |
| 2012-09-30 | 12.15% |
| 2012-06-30 | 12.20% |
| 2012-03-31 | 12.70% |
| 2011-12-31 | 11.50% |
| 2011-09-30 | 7.67% |
| 2011-06-30 | 5.18% |
| 2011-03-31 | 2.95% |
| 2010-12-31 | 1.58% |
| 2010-09-30 | 14.19% |
| 2010-06-30 | 19.86% |
| 2010-03-31 | 20.35% |
| 2009-12-31 | 21.85% |
| 2009-09-30 | 35.14% |
| 2009-06-30 | 28.14% |
| 2009-03-31 | 30.32% |
| 2008-12-31 | 41.63% |
| 2008-09-30 | 23.16% |
| 2008-06-30 | 24.51% |
| 2008-03-31 | 24.97% |
| 2007-12-31 | 18.01% |
| 2007-09-30 | 25.96% |
| 2007-06-30 | 24.63% |
| 2007-03-31 | 24.99% |
| 2006-12-31 | 25.25% |
| 2006-09-30 | 26.34% |
| 2006-06-30 | 28.81% |
| 2006-03-31 | 25.37% |
| 2005-12-31 | 25.76% |
| 2005-09-30 | 25.95% |
| 2005-06-30 | 25.98% |
| 2005-03-31 | 31.53% |
| 2004-12-31 | 33.63% |
| 2004-09-30 | 35.28% |
| 2004-06-30 | 39.14% |
| 2004-03-31 | 41.42% |
| 2003-12-31 | 43.85% |
| 2003-09-30 | 47.84% |
| 2003-06-30 | 37.49% |
